Learn how clinicians tailor antidepressants by diagnosis, symptoms, adverse effects, and next-step strategies for treatment-resistant depression.
|Slideshows|August 29, 2017
6 Signs Your Patient Is at Risk for Treatment-Resistant Depression
What factors predispose patients to TRD and what treatment strategies achieve response? Find out here, with a bonus case vignette.
Advertisement
Advertisement
Related to this article
Explore major depression subtypes—from melancholic to inflammatory—and how they shape symptoms, biology, and treatment choices for better outcomes.
Vortioxetine eases depression in older adults, while cognitive gains stay mixed—showing selective boosts in attention and processing speed, not consistent global improvement.
Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.
TRD often mislabels depression; learn why MDD heterogeneity demands tailored treatments and when “difficult-to-treat” fits better.
First US TRD Awareness Day spotlights treatment-resistant depression, urging earlier recognition, stigma-breaking support, and renewed hope for patients and caregivers.
Rethink “treatment-resistant depression” by adopting difficult-to-treat depression, verifying adequate trials, and stratifying drivers like trauma and inflammation to improve outcomes.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Antipsychotic Plasma Levels in Schizophrenia: Detecting Nonadherence and Guiding Dose Decisions
2
Choosing an Antidepressant: Art, Science, and Knowing Your Patient
3
Can Durable Response to Psilocybin Reshape Treatment-Resistant Depression Care?
4
Responding to Intimate Partner Violence Disclosures in Psychiatry
5